Clinical Cancer Research The Science of Cancer Health Disparities Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dosaka-Akita, H.
Right arrow Articles by Taniguchi, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dosaka-Akita, H.
Right arrow Articles by Taniguchi, N.
Clinical Cancer Research Vol. 10, 1773-1779, March 2004
© 2004 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Expression of N-Acetylglucosaminyltransferase V Is Associated with Prognosis and Histology in Non-Small Cell Lung Cancers

Hirotoshi Dosaka-Akita1, Eiji Miyoshi2, Osamu Suzuki3, Tomoo Itoh4, Hiroyuki Katoh5 and Naoyuki Taniguchi2

1 Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan; 2 Department of Biochemistry, Osaka University Medical School/Graduate School of Medicine, Suita, Japan; 3 First Department of Pathology, Fukushima Medical University, Fukushima, Japan; 4 Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan; and 5 Department of Surgical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: N-Acetylglucosaminyltransferase V (GnT-V), a key enzyme in the formation of branching of asparagine-linked oligosaccharides, is strongly linked to tumor invasion and metastasis of colon and breast cancers. However, GnT-V is expressed in many tissues, including normal lung. GnT-V expression has not been examined previously in human lung cancers. The objective of this study is to examine GnT-V expression in non-small cell lung cancers (NSCLCs) and to determine its relationship to biological and clinicopathological characteristics and prognosis.

Experimental Design: GnT-V expression was studied by immunohistochemistry in 217 surgically resected NSCLCs and analyzed statiscally in relation to various characteristics.

Results: High GnT-V expression was found in 113 (52.1%) NSCLCs, and low GnT-V expression was found in 104 (47.9%) NSCLCs. Multivariate logistic regression analysis revealed a significant association between low GnT-V expression and squamous cell carcinomas, as compared with nonsquamous cell carcinomas (P = 0.02). Among biological characteristics of tumors, Ki-67 labeling index was higher in tumors with low GnT-V expression than in those with high GnT-V expression, although this difference was not statistically significant (P = 0.09). Patients with tumors having low GnT-V expression had significantly shorter survival time than patients with tumors having high GnT-V expression in 103 patients with pStage I NSCLCs (5-year survival rates, 49% and 86%, respectively; P = 0.0009), as well as in 59 patients with pStage I non-squamous cell carcinomas (5-year survival rates, 54% and 89%, respectively; P = 0.007). Low GnT-V expression was a significant unfavorable prognostic factor in pStage I NSCLCs (hazard ratio, 2.86; P = 0.002) and in pStage I nonsquamous cell carcinomas (hazard ratio, 3.02; P = 0.02). Furthermore, ß1–6 branching of asparagine-linked oligosaccharides, which are products of GnT-V, were increased highly or moderately in 8 of 10 tumors with high GnT-V expression, as judged by leukoagglutinating phytohemagglutinin staining.

Conclusions: GnT-V expression is associated with histology in NSCLCs. Low GnT-V expression is associated with shorter survival and poor prognosis in pStage I overall NSCLCs and non-squamous cell carcinomas.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Lung cancer is one of the leading causes of cancer death throughout the world. Although the management and treatment of non-small cell lung cancers (NSCLCs) have improved, there is no evidence to suggest that therapeutic advances have resulted in a marked increase of survival rates, and the overall 5-year survival rate remains <15% (1 , 2) . The clinical observations that patients with NSCLCs in comparable stages may have different clinical courses and may respond differently to similar treatments have yet to be fully understood. A more sophisticated understanding of the pathogenesis and biology of these tumors (3 , 4) could provide useful information for predicting clinical outcome, individualizing treatment (5, 6, 7, 8) , and identifying molecular targets of the treatment (9) .

Oligosaccharides on glycoproteins are altered in tumorigenesis, and they often play a role in the regulation of the biological characteristics of tumors (10) . Each oligosaccharide is synthesized by a specific glycosyltransferase, the expression of which affects specific functions of glycoproteins through glycosylation in normal and malignant cells (11) . Among many glycosyltransferases, N-acetylglucosaminyltransferase V (GnT-V), a key enzyme in the formation of branching of asparagine-linked oligosaccharides, is the most strongly linked to tumor invasion and metastasis in cancers of the colon and breast (12, 13, 14) . In such organs, normal epithelial cells do not express GnT-V (14) or ß1–6 branching asparagine-linked oligosaccharides, which are synthesized by GnT-V (15) . On the other hand, GnT-V has been shown to be expressed in many mouse tissues, including normal lung (16) . In addition, expression of ß1–6 branching asparagine-linked oligosaccharides, which are synthesized by GnT-V, is found in normal human bronchial epithelial cells and alveolar pneumocytes (15) . However, GnT-V expression has not been examined previously in human lung cancers.

In the present study, we examined GnT-V expression by immunohistochemistry in surgically resected NSCLCs and analyzed its biological and clinical importance, especially as a potential prognostic factor.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tumor Specimens and Survival Data.
Primary tumor specimens from 217 NSCLCs were consecutively obtained by surgery performed at the Hokkaido University Medical Hospital between 1976 and 1994. The patients with NSCLCs consisted of 145 men and 72 women. The histological classification of the tumor specimens was based on WHO criteria (17) , and the specimens included 90 squamous cell carcinomas, 109 adenocarcinomas, 9 large cell carcinomas, and 8 adenosquamous cell carcinomas. For this study, non-squamous cell carcinoma included adenocarcinoma, large cell carcinoma, and adenosquamous cell carcinoma. The specimens represented 120 Stage I, 18 Stage II, 71 Stage IIIa, 1 Stage IIIb, and 7 Stage IV tumors. The postsurgical pathological tumor-node-metastasis stage (pTNM) was determined according to the guidelines of the American Joint Committee on Cancer (18) . Of the 120 patients with pStage I tumors resected with curative intent, survival was analyzed for the 103 patients who met the following criteria: (a) survived for >3 months after surgery; (b) did not die of causes other than lung cancer within 5 years after surgery; and (c) were followed for >3 years after surgery (for patients who remained alive). Seventeen patients did not meet the above criteria (four patients died within 3 months after surgery, six died of causes other than lung cancer within 5 years, and seven had no survival records after surgery) were excluded from the survival analysis. Of the 103 patients for whom survival was analyzed, 54 patients had died of cancer. Of these 54 patients, 27 had squamous cell carcinomas, 22 had adenocarcinomas, 3 had large cell carcinomas, and 2 had adenosquamous cell carcinomas. Karnofsky performance status was 90% or greater in all 103 patients for whom survival was analyzed. This study was approved by the Medical Ethical Committee of Hokkaido University School of Medicine. Because all patients were coded, they could not be individually identified.

Immunohistochemistry for GnT-V.
GnT-V expression was analyzed by immunohistochemistry. The labeled streptavidin biotin method was used on 4-µm sections of formalin-fixed, paraffin-embedded tissues after deparaffinization. Briefly, deparaffinized tissue sections were incubated with normal rabbit serum at room temperature to block nonspecific antibody binding sites. The sections were consecutively reacted with a mouse monoclonal antibody against recombinant human GnT-V (1:400 dilution; Ref. 14 ) or with control mouse isotype-specific immunoglobulin at 4°C overnight. Immunostaining was performed by the biotin-streptavidin immunoperoxidase method with 3,3'-diaminobenzidine as a chromogen (SAB-PO kit; Nichirei, Tokyo, Japan). Methyl green was used for counterstain. GnT-V expression found in normal bronchial epithelial cells and alveolar pneumocytes served as internal positive controls.

GnT-V expression in tumors was classified as high or low, based on the proportion of positively stained cancer cells (>=50% of cancer cells stained or <50% of cancer cells stained) and the staining intensity (classified as retained or decreased and negative, as compared with the staining of normal bronchial epithelial cells). Tumors that retained staining in at least 50% of cancer cells were judged as having high GnT-V expression (retaining expression of GnT-V). Tumors that retained staining in <50% of cancer cells were judged as having low GnT-V expression (losing expression of GnT-V).

Immunohistochemistry for Ki-67, p27KIP1, Cyclin E, and GalNAc-T3.
Expression of Ki-67, p27KIP1, cyclin E, and GalNAc-T3 was analyzed by immunohistochemistry. For these proteins, the slides and results that were reported previously (19, 20, 21) were used for the present study. The methods for the staining of these proteins in resected tumors have been described previously (19, 20, 21) . The labeled streptavidin biotin method was used on 4-µm sections of formalin-fixed, paraffin-embedded tissues after deparaffinization. The primary antibodies used were a mouse monoclonal MIB-1 antibody (Immunotech, Marseilles, France), a mouse monoclonal antihuman p27KIP1 antibody (clone 1B4; Novocastra, Newcastle, United Kingdom), a mouse monoclonal antihuman cyclin E antibody (HE12; PharMingen, San Diego, CA), and a rabbit polyclonal antibody against a synthesized peptide of human GalNAc-T3 (21) .

Leukoagglutinating Phytohemagglutinin (L-PHA) Histochemistry.
Expression of ß1–6 branching asparagine-linked oligosaccharides was analyzed by L-PHA histochemistry. The labeled streptavidin biotin method was used on 4-µm sections of formalin-fixed, paraffin-embedded tissues after deparaffinization, as described previously (22) . Briefly, trypsinization was done in Tris buffer containing 0.1% trypsin (Difco Laboratories, Detroit, MI) and 0.1% CaCl2 for 10 min at 37°C after blocking endogenous peroxidase activity. To remove sialic acids from the terminal residues of L-PHA-reactive oligosaccharides, the sections were treated with neuraminidase from Vibrio Cholerae (Roche, Tokyo, Japan) at a concentration of 0.1 unit/ml in sodium acetate buffer (pH 5.6) containing 0.04 M CaCl2 for 1 h at 37°C. The sections were incubated with 5% skim milk in PBS for 20 min at room temperature to block nonspecific staining. The sections were incubated with biotinylated L-PHA lectins (E.Y. Laboratories Inc., San Mateo, CA) at a dilution of 1:500 at 4°C overnight. Staining was performed by the biotin-streptavidin peroxidase method with 3,3'-diaminobenzidine as a chromogen (Nichirei). Hematoxylin was used for counterstain.

L-PHA binding reactivity was classified as high, moderate, or low, according to the proportion of positively stained cancer cells (>=30%, between 10% and 30%, or <10%, respectively).

Statistical Analysis.
The associations between GnT-V expression and categorical variables were analyzed by the {chi}2 test or Fisher’s exact test, as appropriate. The associations between GnT-V expression and age or Ki-67 labeling index (LI) were analyzed by Student’s t test. To simultaneously examine the effect of more than one factor on GnT-V expression, multivariate logistic regression analysis was used (23) . The survival curves were estimated using the Kaplan-Meier method, and differences in survival distributions were evaluated by the generalized Wilcoxon test. Cox’s proportional hazards modeling of factors potentially related to survival was performed to identify which factors might have a significant influence on survival. Ps < 0.05 were considered statistically significant. All tests were two-sided.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Typical immunostaining patterns for GnT-V in normal bronchial tissue and NSCLCs are shown in Fig. 1Citation . Normal bronchial epithelial cells, bronchial gland cells, and alveolar pneumocytes (data not shown) showed GnT-V expression, consistent with previous findings that GnT-V is expressed in normal mouse lung (16) and that ß1–6 branching oligosaccharides synthesized by GnT-V are found in normal bronchial epithelial cells and alveolar pneumocytes (15) . In cancer cells, GnT-V expression was found diffusely in the cytoplasm or localized in the Golgi apparatus, as reported previously for colon cancers (14) .



View larger version (144K):
[in this window]
[in a new window]
  		Fig. 1. Immunohistochemical staining patterns for N-acetylglucosaminyltransferase V (GnT-V) in normal bronchial tissue and non-small cell lung cancers. Normal bronchial epithelial cells (A) and bronchial gland cells (B) show GnT-V expression. An adenocarcinoma tumor shows high GnT-V expression diffusely in the cytoplasm (C), and a squamous cell carcinoma tumor shows low GnT-V expression (D). Scale bar = 20 µm.

 
High GnT-V expression was found in 113 (52.1%) NSCLCs, and low GnT-V expression was found in 104 (47.9%) NSCLCs (Table 1)Citation . Low GnT-V expression was significantly more prevalent in tumors from men than in those from women (P = 0.009), in tumors from smokers compared with nonsmokers (P = 0.04), and in squamous cell carcinomas compared with non-squamous cell carcinomas (P = 0.003) by the {chi}2 test (Table 1)Citation . GnT-V expression was not associated with pTNM classifications or pStage. Multivariate logistic regression analysis for the correlation between GnT-V expression and various characteristics showed a significant association between low GnT-V expression and squamous cell carcinomas (P = 0.02; Table 2Citation ).


View this table:
[in this window]
[in a new window]
  		Table 1 Relationship between GnT-Va expression and clinical and clinicopathological characteristics in 217 surgically resected NSCLCs

 

View this table:
[in this window]
[in a new window]
  		Table 2 Multivariate logistic regression analysis for the correlation between GnT-Va expression and clinical and clinicopathological characteristics

 
Among biological characteristics of tumors studied previously in this cohort of NSCLCs (19, 20, 21) , Ki-67 LI was higher in tumors with low GnT-V expression than in those with high GnT-V expression, although this difference was not statistically significant (P = 0.09; Table 3Citation ). Low GalNAc-T3 expression was significantly more prevalent in tumors with low GnT-V expression than in those with high GnT-V expression (P = 0.0001). There were no differences in p27KIP1 LI and cyclin E LI between tumors with low GnT-V expression and those with high GnT-V expression.


View this table:
[in this window]
[in a new window]
  		Table 3 Relationship between GnT-Va expression and cell biological characteristics

 
We next analyzed the relationship between GnT-V expression and patient survival (Fig. 2)Citation and the importance of GnT-V as a prognostic factor (Table 4)Citation in pStage I disease. In 103 patients with pStage I NSCLCs, patients with tumors having low GnT-V expression survived a significantly shorter time than patients with tumors having high GnT-V expression (5-year survival rates, 49% and 86%, respectively; P = 0.001; Fig. 2ACitation ). Low GnT-V expression was the only significant unfavorable prognostic factor (hazard ratio, 2.86; P = 0.002) found in our analysis (Table 4A)Citation . Squamous cell carcinomas and non-squamous cell carcinomas were analyzed separately because histology was significantly correlated with GnT-V expression in the multivariate logistic regression analysis (Table 2)Citation . In 59 patients with pStage I non-squamous cell carcinomas, patients with tumors having low GnT-V expression survived a significantly shorter time than patients with tumors having high GnT-V expression (5-year survival rates, 54% and 89%, respectively; P = 0.007; Fig. 2BCitation ). Low GnT-V expression was the only significant unfavorable prognostic factor (hazard ratio, 3.02; P = 0.02) in pStage I non-squamous cell carcinomas that we found from our analysis (Table 4B)Citation . In 44 patients with pStage I squamous cell carcinomas, GnT-V expression was not associated with survival (5-year survival rates, 47% for low GnT-V expression and 75% for high GnT-V expression; P = 0.2) and was not a prognostic factor (P = 0.1).



View larger version (28K):
[in this window]
[in a new window]
  		Fig. 2. Kaplan-Meier survival curves for patients with non-small cell lung cancers. Survival curves for patients with pStage I tumors are stratified by low and high N-acetylglucosaminyltransferase V expression for overall non-small cell lung cancers (n = 103; A) and for non-squamous cell carcinomas (n = 59; B).

 

View this table:
[in this window]
[in a new window]
  		Table 4 Cox’s proportional hazards model analysis of prognostic factors in patients with pStage I NSCLCsa

 
We examined the expression of ß1–6 branching asparagine-linked oligosaccharides by L-PHA histochemistry in 10 randomly selected NSCLCs with high GnT-V expression and 10 randomly selected NSCLCs with low GnT-V expression to determine whether GnT-V expression resulted in the synthesis of ß1–6 branching oligosaccharides (Fig. 3Citation , Table 5Citation ). L-PHA binds with high specificity and affinity to complex-type tri- and tetra-antennary oligosaccharides, which contain ß1–6 branches (24) . Hence, L-PHA has been used as a reliable reagent to detect ß1–6 branching oligosaccharides by histochemistry (13 , 25) . Among the 10 tumors with high GnT-V expression, 6 tumors had high L-PHA staining, and 2 tumors had moderate L-PHA staining. Among the 10 tumors with low GnT-V expression, 6 tumors had low L-PHA staining, and 2 tumors had moderate L-PHA staining.



View larger version (161K):
[in this window]
[in a new window]
  		Fig. 3. Immunohistochemical staining patterns for N-acetylglucosaminyltransferase V (GnT-V; A and C) and staining patterns for leukoagglutinating phytohemagglutinin (L-PHA; B and D) in non-small cell lung cancers. The staining pattern of a tumor with high GnT-V expression and high L-PHA staining is shown in A and B. Staining for a tumor with low GnT-V expression and low L-PHA staining is shown in C and D. GnT-V expression is found as Golgi localization in the cytoplasm of tumor cells (A). L-PHA-reactive glycoconjugates are found diffusely in the tumor cells (B). GnT-V expression is not found in most of the tumor cells (C), and L-PHA-reactive glycoconjugates are not found in most of the tumor cells (D). Scale bar = 20 µm.

 

View this table:
[in this window]
[in a new window]
  		Table 5 Relationship between GnT-Va expression and L-PHA staining in NSCLCs

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In the present study, we demonstrate that GnT-V expression is decreased or lost in about half of NSCLCs, although GnT-V is expressed in bronchial epithelial cells, bronchial gland cells, and alveolar pneumocytes. Histology was significantly correlated with GnT-V expression; low GnT-V expression was more frequently found in squamous cell carcinomas than in non-squamous cell carcinomas. Furthermore, low GnT-V expression was associated with a shorter survival period and was an unfavorable prognostic factor in pStage I resected non-squamous cell carcinomas.

GnT-V expression is not equal to the expression of ß1–6 branching asparagine-linked oligosaccharides analyzed by L-PHA histochemistry, because (a) GnT-V has been shown to have a function as an inducer of angiogenesis (26) that is a completely different function from the original function of glycosyltransferase, and (b) GnT-V expression does not necessarily result in the synthesis of ß1–6 branching oligosaccharides, depending on the cell and tissue types (data not shown). Therefore, we analyzed the relationship between GnT-V expression and L-PHA staining in selected specimens of NSCLCs. As a result, in 8 of 10 tumors with high GnT-V expression, there was high or moderate L-PHA staining, indicating the synthesis of ß1–6 branching oligosaccharides.

Interestingly, in this study, only 1 of 8 goblet cell-type adenocarcinomas (27) had high GnT-V expression (data not shown), although 70 of 109 overall adenocarcinomas had high GnT-V expression (Table 1)Citation . Goblet cell-type adenocarcinoma is supposed to be an independent subtype that is distinct from other cell types of adenocarcinoma with respect to molecular biological and immunohistochemical features (28 , 29) . Normal bronchial goblet cells are negative for ß1–6 branching oligosaccharides synthesized by GnT-V (15) . Collectively, these findings suggest cell type-specific and developmentally regulated modes of GnT-V expression. When the eight goblet cell-type adenocarcinomas were excluded from the analysis, Ki-67 LI was significantly lower in tumors with high GnT-V expression than in tumors with low GnT-V expression (mean ± SD, 34.0 ± 26.1 and 41.7 ± 28.4, respectively; P = 0.04). This finding of low KI-67 LI in tumors with high GnT-V expression is consistent with that in hepatoma (30) .

Li et al. (15) reported expression of ß1–6 branching, asparagine-linked oligosaccharides, which are products of GnT-V, in almost all postmitotic, fully differentiated epithelial cell types of normal human and rat tissues, including bronchial epithelial cells and alveolar pneumocytes. Exceptions were the epithelia of the colon, esophagus, and resting mammary gland, which showed no expression of ß1–6 branching oligosaccharides. Increased GnT-V activity and ß1–6 branching oligosaccharides were found in human colon and breast cancers, as compared with the respective normal epithelium (12 , 31) . In cancers derived from these epithelia and experimental tumors, GnT-V expression has been shown to be linked to malignant transformation, invasion, and metastatic potential (25 , 31, 32, 33, 34, 35, 36, 37, 38) , as well as unfavorable prognosis of patients bearing tumors (14 , 27) . In these tumors, glycoproteins, such as integrins (34 , 39) , lysosomal-associated membrane protein 2 (34 , 36) , and matriptase (40) , have been shown to be target glycoproteins that are glycosylated by GnT-V.

However, in NSCLCs, which derive from bronchial and alveolar epithelia that normally express GnT-V, GnT-V expression was associated with favorable prognosis in this study. The biological importance of GnT-V expression for maintaining physiological function, as well as for the development and progression of cancer, may be different in each organ and tissue, depending on the biological function of target substrate glycoproteins, which can vary among organs and tissues. GnT-V expression is regulated in a tissue-specific manner (16) , and certain cancer-associated loss or gain in glycosylation by GnT-V may contribute directly to cellular transformation (34) . Decreased (low) expression of GnT-V may contribute to altered biological properties of NSCLCs by decreased synthesis of ß1–6 branching oligosaccharides of certain target glycoproteins, resulting in a shorter survival of patients having tumors with low GnT-V expression compared with those having tumors with high GnT-V expression. The target glycoproteins of GnT-V in the lung and bronchus remain to be determined.

In conclusion, decreased GnT-V expression is found in about half of NSCLCs in association with the histology and is associated with an unfavorable clinical outcome in pStage I overall NSCLCs and non-squamous cell carcinomas. GnT-V expression may have great value in stratification of patients with pStage I tumors into groups at high and low risks of recurrence in NSCLCs (especially in non-squamous cell carcinomas) and thus in selecting patients who will benefit from adjuvant therapy.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Hirotoshi Dosaka-Akita, Department of Medical Oncology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan. Phone: 81-11-706-5551; Fax: 81-11-706-5077; E-mail: hdakita{at}med.hokudai.ac.jp

Received 7/15/03; revised 11/20/03; accepted 12/ 3/03.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ginsberg R. J., Vokes E. E., Rosenzweig K. Non-small cell lung cancer DeVita V. T. Hellma S. Rosenberg S. A. eds. . Cancer: Principles and Practice of Oncology, 6th ed. 925-982, Lippincott-Raven Publishers Philadelphia 2001.
  2. Carney D. N. Lung cancer: time to move on from chemotherapy. N. Engl. J. Med., 346: 126-128, 2002.[Free Full Text]
  3. Sekido Y., Fong K. M., Minna J. D. Molecular genetics of lung cancer Caskey C. T. Austin C. Hoxie J. eds. . Annual Review of Medicine, Vol. 54: 73-87, Annual Reviews Palo Alto 2003.[CrossRef]
  4. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.[CrossRef][Medline]
  5. Strauss G. M., Kwiatkowski D. J., Harpole D. H., Lynch T. J., Skarin A. T., Sugarbaker D. J. Molecular and pathologic markers in stage I non-small cell carcinoma of the lung. J. Clin. Oncol., 13: 1265-1279, 1995.[Abstract]
  6. Harpole D. H., Jr., Herndon J. E., II, Wolfe W. G., Iglehart J. D., Marks J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res., 55: 51-56, 1995.[Abstract/Free Full Text]
  7. Kwiatkowski D. J., Harpole D. H., Jr., Goleski J., Herndon J. E., II, Dar-Bin S., Richards W., Blanco R., Xu H., Strauss G. M., Sugarbaker D. J. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J. Clin. Oncol., 16: 2468-2477, 1998.[Abstract]
  8. Dosaka-Akita H., Hommura F., Mishina T., Ogura S., Shimizu M., Katoh H., Kawakami Y. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res., 61: 2500-2504, 2001.[Abstract/Free Full Text]
  9. Gibbs J. B. Mechanism-based target identification and drug discovery in cancer research. Science (Wash. DC), 287: 1969-1973, 2000.[Abstract/Free Full Text]
  10. Hakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res., 52: 257-331, 1989.[Medline]
  11. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 3: 97-130, 1993.[Abstract/Free Full Text]
  12. Fernandes B., Sagman U., Auger M., Demetriou M., Dennis J. W. ß1–6 Branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res., 51: 718-723, 1991.[Abstract/Free Full Text]
  13. Seelentag W. K., Li W. P., Schmitz S. F., Metzger U., Aeberhard P., Heitz P. U., Roth J. Prognostic value of ß1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res., 58: 5559-5564, 1998.[Abstract/Free Full Text]
  14. Murata K., Miyoshi E., Kameyama M., Ishikawa O., Kabuto T., Sasaki Y., Hiratsuka M., Ohigashi H., Ishiguro S., Ito S., Honda H., Takemura F., Taniguchi N., Imaoka S. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin. Cancer Res., 6: 1772-1777, 2000.[Abstract/Free Full Text]
  15. Li W. P., Roth J. Expression of ß1,6 branched asparagine-linked oligosaccharides in non-mitotic and non-migratory cells of normal human and rat tissues. Int. J. Cancer, 71: 483-490, 1997.[CrossRef][Medline]
  16. Perng G. S., Shoreibah M., Margitich I., Pierce M., Fregien N. Expression of N-acetylglucosaminyltransferase V mRNA in mammalian tissues and cell lines. Glycobiology, 4: 867-871, 1994.[Abstract/Free Full Text]
  17. WHO. Histological typing of lung tumors, 2nd ed.. Am. J. Clin. Pathol, 77: 123-136, 1982.[Medline]
  18. American Joint Committee on Cancer. Lung Beahrs O. H. Henson D. E. Hutter R. V. P. Kennedy B. J. eds. . Manual for Staging of Cancer, 4th ed. 15-122, J. B. Lippincott Co. Philadelphia 1992.
  19. Hommura F., Dosaka-Akita H., Mishina T., Nishi M., Kojima T., Hiroumi H., Ogura S., Shimizu M., Katoh H., Kawakami Y. Prognostic significance of p27KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin. Cancer Res., 6: 4073-4081, 2000.[Abstract/Free Full Text]
  20. Mishina T., Dosaka-Akita H., Hommura F., Nishi M., Kojima T., Ogura S., Shimizu M., Katoh H., Kawakami Y. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin. Cancer Res., 6: 11-16, 2000.[Abstract/Free Full Text]
  21. Dosaka-Akita H., Kinoshita I., Yamazaki K., Izumi H., Itoh T., Katoh H., Nishimura M., Matsuo K., Yamada Y., Kohno K. N-Acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br. J. Cancer, 87: 751-755, 2002.[CrossRef][Medline]
  22. Suzuki O., Nozawa Y., Kawaguchi T., Abe M. Phaseolus vulgaris leukoagglutinating lectin-binding reactivity in human diffuse large B cell lymphoma and its relevance to the patient’s clinical outcome: lectin histochemistry and lectin blot analysis. Pathol. Int., 49: 874-880, 1999.[CrossRef][Medline]
  23. Cox D., Snell E. . Analysis of Binary Data, 2nd ed. Chapman and Hall London 1989.
  24. Cummings R. D., Kornfeld S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J. Biol. Chem., 257: 11230-11234, 1982.[Abstract/Free Full Text]
  25. Li W. P., Zuber C., Heitz P. U., Roth J. Cytochemical staining for ß1,6 branching of asparagine-linked oligosaccharides in variants of metastatic human colon carcinoma cells. Am. J. Pathol., 145: 470-480, 1994.[Abstract]
  26. Saito T., Miyoshi E., Sasai K., Nakano N., Eguchi H., Honke K., Taniguchi N. A secreted type of ß1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation: a novel function of GnT-V distinct from the original glycosyltransferase activity. J. Biol. Chem., 277: 17002-17008, 2002.[Abstract/Free Full Text]
  27. Shimosato Y., Kodama T., Kameya T. Morphogenesis of peripheral type adenocarcinoma of the lung Shimosato Y. Melamed M. R. Nettesheim P. eds. . Morphogenesis of Lung Cancer, Vol. 1: 65-89, CRC Press Boca Raton, FL 1982.
  28. Konishi T., Lin Z., Fujino S., Kato H., Mori A. Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Hum. Pathol., 28: 544-548, 1997.[CrossRef][Medline]
  29. Maeshima A., Miyagi A., Hirai T., Nakajima T. Mucin-producing adenocarcinoma of the lung, with special reference to goblet cell type adenocarcinoma: immunohistochemical observation and Ki-ras gene mutation. Pathol. Int., 47: 454-460, 1997.[Medline]
  30. Ito Y., Miyoshi E., Sakon M., Takeda T., Noda K., Tsujimoto M., Ito S., Honda H., Takemura F., Wakasa K., Monden M., Matsuura N., Taniguchi N. Elevated expression of UDP-N-acetylglucosamine: {alpha}-mannoside ß1,6 N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int. J. Cancer, 91: 631-637, 2001.[CrossRef][Medline]
  31. Dennis J. W., Laferte S. Oncodevelopmental expression of -GlcNAc ß1–6Man {alpha}1–6Man ß1-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas. Cancer Res., 49: 945-950, 1989.[Abstract/Free Full Text]
  32. Buckhaults P., Chen L., Fregien N., Pierce M. Transcriptional regulation of N-acetylglucosaminyltransferase V by the src oncogene. J. Biol. Chem., 272: 19575-19581, 1997.[Abstract/Free Full Text]
  33. Chen L., Zhang W., Fregien N., Pierce M. The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. Oncogene, 17: 2087-2093, 1998.[CrossRef][Medline]
  34. Demetriou M., Nabi I. R., Coppolino M., Dedhar S., Dennis J. W. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J. Cell Biol., 130: 383-392, 1995.[Abstract/Free Full Text]
  35. Dennis J. W., Laferte S., Waghorne C., Breitman M. L., Kerbel R. S. ß1–6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science (Wash. DC), 236: 582-585, 1987.[Abstract/Free Full Text]
  36. Saitoh O., Wang W. C., Lotan R., Fukuda M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J. Biol. Chem., 267: 5700-5711, 1992.[Abstract/Free Full Text]
  37. Takano R., Nose M., Nishihira T., Kyogoku M. Increase of ß1–6-branched oligosaccharides in human esophageal carcinomas invasive against surrounding tissue in vivo and in vitro. Am. J. Pathol., 137: 1007-1011, 1990.[Abstract]
  38. Granovsky M., Fata J., Pawling J., Muller W. J., Khokha R., Dennis J. W. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat. Med., 6: 306-312, 2000.[CrossRef][Medline]
  39. Guo H. B., Lee I., Kamar M., Akiyama S. K., Pierce M. Aberrant N-glycosylation of ß1 integrin causes reduced {alpha}5ß1 integrin clustering and stimulates cell migration. Cancer Res., 62: 6837-6845, 2002.[Abstract/Free Full Text]
  40. Ihara S., Miyoshi E., Ko J. H., Murata K., Nakahara S., Honke K., Dickson R. B., Lin C. Y., Taniguchi N. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding ß1–6 GlcNAc branching. J. Biol. Chem., 277: 16960-16967, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
O. Vagin, E. Tokhtaeva, I. Yakubov, E. Shevchenko, and G. Sachs
Inverse Correlation between the Extent of N-Glycan Branching and Intercellular Adhesion in Epithelia: CONTRIBUTION OF THE Na,K-ATPase 1 SUBUNIT
J. Biol. Chem., January 25, 2008; 283(4): 2192 - 2202.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-B. Guo, M. Randolph, and M. Pierce
Inhibition of a Specific N-Glycosylation Activity Results in Attenuation of Breast Carcinoma Cell Invasiveness-related Phenotypes: INHIBITION OF EPIDERMAL GROWTH FACTOR-INDUCED DEPHOSPHORYLATION OF FOCAL ADHESION KINASE
J. Biol. Chem., July 27, 2007; 282(30): 22150 - 22162.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. W. Wattenberg
An interlocker concept of carcinogenesis.
Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1425 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Ishimura, T. Takahashi, H. Nakagawa, S.-I. Nishimura, Y. Arai, Y. Horikawa, T. Habuchi, E. Miyoshi, A. Kyan, S. Hagisawa, et al.
N-Acetylglucosaminyltransferase V and {beta}1-6 Branching N-Linked Oligosaccharides Are Associated with Good Prognosis of Patients with Bladder Cancer
Clin. Cancer Res., April 15, 2006; 12(8): 2506 - 2511.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. F. Siddiqui, J. Pawelek, T. Handerson, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp
Coexpression of {beta}1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2517 - 2523.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Handerson, R. Camp, M. Harigopal, D. Rimm, and J. Pawelek
{beta}1,6-Branched Oligosaccharides Are Increased in Lymph Node Metastases and Predict Poor Outcome in Breast Carcinoma
Clin. Cancer Res., April 15, 2005; 11(8): 2969 - 2973.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-i. Fukumoto, N. Yamauchi, H. Moriguchi, Y. Hippo, A. Watanabe, J. Shibahara, H. Taniguchi, S. Ishikawa, H. Ito, S. Yamamoto, et al.
Overexpression of the Aldo-Keto Reductase Family Protein AKR1B10 Is Highly Correlated with Smokers' Non-Small Cell Lung Carcinomas
Clin. Cancer Res., March 1, 2005; 11(5): 1776 - 1785.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dosaka-Akita, H.
Right arrow Articles by Taniguchi, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dosaka-Akita, H.
Right arrow Articles by Taniguchi, N.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online